Description

GLP-3 RT

Triple Incretin Agonist (GLP-1 / GIP / GCGR) / Next-Generation Metabolic Modulator

GLP-3 RT is a triple-agonist peptide designed to simultaneously activate GLP-1, GIP, and glucagon (GCGR) receptors.  Theoretically, this tri-pathway mechanism provides improved the potential for fat-loss efficiency, glucose stability, and metabolic flexibility, addressing multiple energy-regulation systems at once.  By stimulating both incretin and glucagon pathways, energy expenditure, lipid utilization, and overall metabolic rejuvenation are enhanced.

RESEARCH

GLP-3 RT is a synthetic, multi-site peptide analog provided in lyophilized powder form for exclusive use in qualified laboratory environments. This product has not been evaluated by the FDA and is intended solely for in vitro research to explore peptide-receptor interactions and structural modifications under controlled, non-clinical research settings. Use is restricted to trained laboratory personnel in facilities with appropriate safety protocols and institutional oversight.

CHEMICAL INFORMATION

• Molecular Formula: C221H342N46O68
• Molecular Weight: 4731.33 g/mol
• CAS Number: 2381089-83-2

RESEARCH APPLICATIONS

• Receptor-ligand modeling involving peptide analogs
• Evaluation of synthetic conjugation strategies in non-human systems
• Peptide degradation analysis and structural integrity assays
• Receptor pathway simulation and screening assay development

STORAGE AND HANDLING

• Store lyophilized powder at -20°C
• Reconstituted compound should be kept at 2–8°C and used promptly
• Always use sterile technique during handling and preparation.
• Users must follow institutional safety protocols, including appropriate personal protective equipment (PPE) and biosafety measures as required by facility guidelines and applicable regulations. Documentation of proper handling procedures must be maintained.

PRODUCT SPECIFICATION

• Purity: ≥99% (HPLC Verified)
• Appearance: Lyophilized white to off-white powder
• Solubility: Soluble in bacteriostatic water

COMPLIANCE NOTICE

GLP-3 RT is FOR RESEARCH USE ONLY. It is not intended for human or veterinary use. This product has not been evaluated by the FDA and is not to be used for therapeutic, diagnostic, or clinical purposes. Any misuse of this product may violate applicable laws and regulations. By purchasing this product, buyer represents and warrants that it will be used only for in vitro research purposes.

BENEFITS BEING RESEARCHED

• Weight-loss potential through triple incretin activation
• Glycemic control while maintaining lean-mass retention
• Basal metabolic rate and increases fat oxidation
• Cardiovascular and lipid profiles (↓ triglycerides, ↑ HDL)
• Mitochondrial activity and glucose uptake in muscle tissue
• Appetite control and satiety via central metabolic signaling

MECHANISM OF ACTION (Simplified)

• GLP-1 Receptor Activation → enhances insulin secretion, slows gastric emptying, suppresses appetite.
• GIP Receptor Activation → improves insulin sensitivity and lipid metabolism.
• Glucagon Receptor Activation (GCGR) → stimulates fat oxidation and energy expenditure.
• Tri-pathway synergy → balanced improvement in glucose regulation, lipid turnover, and adipose reduction.

FORM / NOTES

• Lyophilized vials for reconstitution
• Standard dual incretin dosing for research use

LEGAL DISCLAIMER

This product is sold strictly for laboratory research use only.

By purchasing this product, the buyer represents and warrants that:

• The material will be used solely for in-vitro research purposes
  • The buyer is qualified to handle laboratory reagents
  • The product will not be used for human or animal consumption, injection, or application

Revyon Technologies assumes no liability for misuse or improper handling.

IMPORTANT NOTICE

Any use outside of stated research purposes is strictly prohibited.